mRNA |
tivozanib |
GDSC1000 |
pan-cancer |
AAC |
0.079 |
0.02 |
mRNA |
BRD8958 |
CTRPv2 |
pan-cancer |
AAC |
0.089 |
0.02 |
mRNA |
pifithrin-alpha |
CTRPv2 |
pan-cancer |
AAC |
0.085 |
0.02 |
mRNA |
masitinib |
CTRPv2 |
pan-cancer |
AAC |
0.082 |
0.02 |
mRNA |
Sunitinib |
GDSC1000 |
pan-cancer |
AAC |
0.12 |
0.02 |
mRNA |
lenvatinib |
CTRPv2 |
pan-cancer |
AAC |
0.082 |
0.02 |
mRNA |
Methotrexate |
CTRPv2 |
pan-cancer |
AAC |
0.083 |
0.02 |
mRNA |
crizotinib:PLX-4032 (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.077 |
0.02 |
mRNA |
alisertib:navitoclax (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.078 |
0.02 |
mRNA |
SNX-2112:bortezomib (250:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.072 |
0.02 |